Disease · MONDO_0005447

testicular cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. testicular cancer. Diseases, record MONDO_0005447. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005447

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: testicular cancer; Open Targets
Open Targets ID: MONDO_0005447; Open Targets
Other names: cancer of testis, malignant neoplasm of testis, malignant neoplasm of the testis, malignant testicular neoplasm, malignant testicular tumor, malignant testicular tumour, malignant testis neoplasm, malignant tumor of testis, malignant tumor of the testis, malignant tumour of testis, malignant tumour of the testis, testicular carcinoma, testis cancer; Open Targets
Disease Ontology: DOID:2998; Disease Ontology
MeSH: D013736; MeSH
NCI Thesaurus: C7251; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 27 drugs, from TTD; Open Targets

Drugs27

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ETOPOSIDE	CHEMBL44657	Small molecule	Approval	TTD	4	3	3	Drugs and targets
PLICAMYCIN	CHEMBL1237054	Small molecule	Approval	TTD	1	0	0	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
DACTINOMYCIN	CHEMBL1554	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
IFOSFAMIDE	CHEMBL1024	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 27

See all 27 drugs

Targets45

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 binding agent; Programmed cell death 1 ligand 1 other	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	2	Granulocyte colony stimulating factor receptor agonist	Phase 2	https://conductscience.org/library/genes/1441	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	2	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 45

See all 45 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03013491	PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas	Phase 1/2	196	2025-06-17	Solid Tumor, Lymphoma	IPILIMUMAB, PACMILIMAB, VEMURAFENIB	Its record names the disease	ClinicalTrials.gov
NCT00003014	Radiation Therapy Compared With Chemotherapy in Treating Patients With Stage I Testicular Cancer	Phase 3	800		Testicular Germ Cell Tumor	CARBOPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00060255	High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors	Phase 2	451		Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific	BUSULFAN, CARBOPLATIN, CARMUSTINE, CYCLOPHOSPHAMIDE, ETOPOSIDE, MELPHALAN, THIOTEPA	Its record names the disease	ClinicalTrials.gov
NCT06684327	Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors	Phase 2	100		Paget Disease, Extramammary, Rhabdomyosarcoma, Testicular Cancer, Penile Cancer, Urachal Cancer	CISPLATIN, IFOSFAMIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00001270	Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma	Phase 1	85		Breast Neoplasms, Lymphoma, Neoplasm Metastasis, Testicular Neoplasms	CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE	Its record names the disease	ClinicalTrials.gov
NCT01782339	A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis	Phase 2	45		Germ Cell Tumour	DACTINOMYCIN, FILGRASTIM, METHOTREXATE, OXALIPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT06309732	GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)	Phase 2	36		Testicular Neoplasms	CISPLATIN, DACTINOMYCIN, EPIRUBICIN, ETOPOSIDE, METHOTREXATE, PEGFILGRASTIM	Its record names the disease	ClinicalTrials.gov
NCT03339635	Short-term Testosterone Replacement in Testicular Cancer Survivors	Phase 2	32		Testicular Cancer	TESTOSTERONE	Its record names the disease	ClinicalTrials.gov
NCT00183820	Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients With Refractory Germ Cell Carcinoma	Phase 2	30		Testicular Cancer, Germ Cell Neoplasm	GEMCITABINE, OXALIPLATIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT06814496	Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors	Phase 1/2	30		Melanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated Carcinoma, Esthesioneuroblastoma, Bladder Cancer, Testicular Cancer, Glioblastoma Multiforme, Cervical Cancer, Large Cell Neuroendocrine Carcinoma of the Lung, Non Small Cell Lung Cancer, Merkel Cell Carcinoma	TARLATAMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
CX-072 10 mg/kg (Part A and Part A2) vs CX-072 10 mg/kg (Part D): The Percentage of Subjects Experiencing Anti-cancer Activity (ORR) When Given 10 mg/kg CX-072 as Monotherapy	1 of 16	13 of 98	114	NCT03013491

Source Trial comparisons

Papers from its trials7

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28039265	RESULT	1	PubMed
21282539	RESULT	1	PubMed
16039331	RESULT	1	PubMed
15999102	RESULT	1	PubMed
34301809	DERIVED	1	PubMed
34301808	DERIVED	1	PubMed
31953313	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005447

GET https://conductscience.org/api/diseases/v1/MONDO_0005447/drugs?page=2

API reference For AI assistants